Cardiovascular · Small molecule (oral, once daily)

Muvalaplin

Muvalaplin is an experimental daily pill that lowers lipoprotein(a) by blocking its formation, the first oral approach to reach a Phase 3 cardiovascular outcomes trial. Phase 2 reductions ranged up to about 86% depending on how Lp(a) was measured.

Not yet approvedFirst oral Lp(a)-lowering drug in a Phase 3 outcomes trial (MOVE-Lp(a)), now recruiting

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperEli Lilly and Company · Eli Lilly and Company pipeline
Drug typeSmall molecule (oral, once daily)
TargetLipoprotein(a) formation (apolipoprotein(a))
MechanismInhibits the formation of lipoprotein(a), preventing apolipoprotein(a) from assembling with the lipoprotein particle
Other namesLY3473329

Key points

  • Muvalaplin is an oral small molecule that inhibits the formation of lipoprotein(a) [Lp(a)], rather than reducing its production.
  • In the 233-patient Phase 2 KRAKEN trial, placebo-adjusted Lp(a) reductions were 81.7% to 85.8% at higher doses using an intact-Lp(a) assay, and about 70% using a standard apolipoprotein(a)-based assay.
  • The difference between assays matters: it shows that how Lp(a) is measured can change the size of the reported effect.
  • MOVE-Lp(a), a Phase 3 cardiovascular outcomes trial with an estimated 10,450 participants, is recruiting. The registry estimates primary completion in March 2031.
  • No safety or tolerability concerns were observed in KRAKEN, but the trial was small and lasted only 12 weeks.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Elevated lipoprotein(a) with cardiovascular disease
MOVE-Lp(a) cardiovascular outcomes trial is recruiting (registry).
Phase 32
1 active · 1 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What muvalaplin is

Muvalaplin is an oral small-molecule drug developed by Eli Lilly that inhibits the formation of lipoprotein(a), or Lp(a). Most Lp(a) drugs in development, such as pelacarsen, olpasiran, and lepodisiran, are injectable nucleic-acid drugs that stop the liver from making apolipoprotein(a). Muvalaplin works differently: it interferes with apolipoprotein(a) assembling with the lipoprotein particle to form Lp(a). It is taken once a day by mouth.

Why the target matters

Lp(a) is a largely inherited cardiovascular risk factor. A 2009 study in JAMA found that people with genetically elevated Lp(a) had a higher risk of heart attack, which supports a causal role and the case for lowering it. There is no approved drug that specifically lowers Lp(a).

Clinical evidence

Phase 1

According to the Phase 2 publication, a 14-day Phase 1 study found muvalaplin was well tolerated and reduced Lp(a) by up to 65%.

Phase 2: KRAKEN

KRAKEN was a 12-week, placebo-controlled trial in 233 adults at high cardiovascular risk with elevated Lp(a), published in JAMA in 2025.

Daily dose Placebo-adjusted Lp(a) change (intact Lp(a) assay) Placebo-adjusted Lp(a) change (apolipoprotein(a)-based assay)
10 mg −47.6% −40.4%
60 mg −81.7% −70.0%
240 mg −85.8% −68.9%

Source: Nicholls et al., JAMA (2025).

Apolipoprotein B fell by 8.9% to 16.1%, and there was no change in high-sensitivity C-reactive protein, a marker of inflammation. The investigators observed no safety or tolerability concerns at any dose.

Phase 3: MOVE-Lp(a)

MOVE-Lp(a) compares muvalaplin with placebo for preventing major cardiovascular events in adults with elevated Lp(a). ClinicalTrials.gov lists an estimated 10,450 participants, recruitment beginning in September 2025, and an estimated primary completion in March 2031.

Scientific perspective

Why two assays give two answers

KRAKEN reported two sets of results because standard Lp(a) tests measure apolipoprotein(a). A drug that blocks apolipoprotein(a) from joining the particle could leave free apolipoprotein(a) in the blood, which a standard test would still count. An intact-particle assay measures only assembled Lp(a). The roughly 15-point gap between the two methods at higher doses is a reminder that a lab measurement is not the same as a clinical effect. See What Is a Primary Clinical Trial Endpoint?

After Lp(a)HORIZON

Pelacarsen's 2026 outcomes trial showed that lowering Lp(a) by about 78% did not reduce cardiovascular events in that population. Muvalaplin's reductions are of a broadly similar order on the standard assay. Whether a different mechanism, daily oral dosing, or a different trial design changes the outcome is unknown. MOVE-Lp(a) is the trial that will answer it, years from now.

Development perspective

  • Regulatory status: muvalaplin has no FDA approval.
  • Timing: MOVE-Lp(a) is the latest of the major Lp(a) outcomes trials to report, with an estimated primary completion in 2031. By then, the results of injectable Lp(a) drugs' outcomes trials should largely determine expectations for the class.
  • Practical appeal: if the class succeeds, a daily pill could be easier to prescribe and start than an injection, although adherence to daily dosing is a known challenge for long-term preventive drugs.
  • Historical benchmark: about 52% of programs that have reached Phase 3 have eventually been approved. This average does not account for the 2026 pelacarsen result.

Competitive context

Muvalaplin is Lilly's second Lp(a) drug, alongside the injectable siRNA lepodisiran. It is the only oral Lp(a)-lowering drug among the agents profiled on this site.

Development timeline

  1. Nov 24, 2022KRAKEN Phase 2 trial begins. Registry
  2. Jan 21, 2025KRAKEN results published: placebo-adjusted Lp(a) reductions of up to 85.8% (intact assay) and about 70% (apolipoprotein(a)-based assay). Peer-reviewed
  3. Sep 2, 2025MOVE-Lp(a) Phase 3 cardiovascular outcomes trial begins. Registry
  4. Sep 4, 2026Read-across: pelacarsen, an injectable Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported

What could change the outlook

  • Progress of MOVE-Lp(a), including any registry amendments to size, endpoint, or timing after the pelacarsen result.
  • Earlier Lp(a) outcomes trial results (olpasiran, then lepodisiran), which will shape expectations for the whole class before MOVE-Lp(a) reads out.
  • Long-term safety data. A daily pill taken for years requires a different safety record than an infrequent injection.
  • Clarification of which Lp(a) assay best reflects the drug's true effect, given the gap between measurement methods in Phase 2.

Clinical trials

6 registered trials list Muvalaplin as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Elevated lipoprotein(a) with cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
MOVE-Lp(a) · NCT07157774
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Phase 3Recruiting10,450 (est.)Mar 2031 (est.)No
KRAKEN · NCT05563246
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Phase 2Completed233Mar 14, 2024Yes

Clinical pharmacology and supporting studies

4 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT04472676
A Study of LY3473329 in Healthy Participants
Phase 1Completed86Nov 9, 2021No
NCT05778864
A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Phase 1Completed47Sep 6, 2024No
NCT05038787
A Study of LY3473329 in Healthy Japanese Participants
Phase 1Completed24Apr 7, 2022No
NCT06342596
A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants
Phase 1Completed16May 1, 2024No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Nicholls SJ, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial (KRAKEN). JAMA. 2025;333(3):222–231.Peer-reviewed
  2. ClinicalTrials.gov. MOVE-Lp(a) (NCT07157774).Registry
  3. ClinicalTrials.gov. KRAKEN (NCT05563246).Registry
  4. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.Peer-reviewed
  5. American Heart Association Newsroom. Lp(a) HORIZON trial results (AHA Scientific Sessions 2026).Scientific meeting
  6. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.